Enteropathy precedes type 1 diabetes in the BB rat.
OBJECTIVE
There is increasing evidence implicating intestinal immune responses to dietary proteins in the pathogenesis of type 1 autoimmune diabetes (T1D). Here we investigated the association between intestinal pathology and dietary factors in T1D by examining the mucosal architecture in the BB rat model.


METHODS
BB control (BBc) and diabetes prone (BBdp) rats were fed either a diabetes retardant hydrolysed casein based diet or one of two cereal based diets that promote the development of diabetes. Intestinal architecture was assessed in the jejunum by microdissection, histology, and immunohistology, and by measuring peroxidase activity and brush border invertase levels.


RESULTS
Enteropathy was present in BBdp rats soon after weaning, as assessed by increases in crypt length and in the proliferative activity of crypt epithelial cells in the jejunum, and this remained constant until 120 days of age. There was also a decrease in invertase activity, as well as increased numbers of intraepithelial lymphocytes, increased levels of mucosal peroxidase activity, and infiltration of the mucosa by CD4(+) T lymphocytes. Equivalent enteropathy was present at all times in BBdp rats and was not influenced by the nature of the diet or by thymectomy at three weeks at age, procedures which prevent the development of diabetes.


CONCLUSIONS
Enteropathy is a consistent feature in the diabetes prone BB rat but it precedes the onset of insulitis and appears to be due to mechanisms distinct from those which cause diabetes. The beneficial effects of the diabetes retardant hydrolysed casein diet on diabetes are not due to an effect on intestinal architecture per se but mucosal damage may be necessary for the development of autoreactivity in the pancreas.
Graham
S
S
Department of Immunology and Bacteriology, University of Glasgow, Western Infirmary, Glasgow G11 6NT, Scotland, UK.
Courtois
P
P
Malaisse
W J
WJ
Rozing
J
J
Scott
F W
FW
Mowat
A Mc I
AM
D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000201:enzymology / Q000209:etiology / Q000473:pathology*; D003922:Diabetes Mellitus, Type 1 / Q000201:enzymology / Q000209:etiology / Q000473:pathology*; D004032:Diet / Q000009:adverse effects; D005260:Female; D007410:Intestinal Diseases / Q000201:enzymology / Q000209:etiology / Q000473:pathology*; D007413:Intestinal Mucosa / Q000201:enzymology; D007583:Jejunum / Q000473:pathology; D008297:Male; D011236:Prediabetic State / Q000201:enzymology / Q000209:etiology / Q000473:pathology*; D051381:Rats; D011913:Rats, Inbred BB; D013950:Thymus Gland / Q000503:physiopathology; D043324:beta-Fructofuranosidase / Q000378:metabolism
D043324:beta-Fructofuranosidase